SI-BONE, Inc.

The carrying value of the Company s long-term debt also approximates fair value based on management s estimation that a current interest rate would not differ materially from the stated rate.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company s fair value of the long-term debt fell under the Level 2 hierarchy.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Pursuant to the Original Loan Agreement, the Company borrowed a term loan in the aggregate principal amount of $ 35.0 million to the Company (the "Original Term Loan").

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Upon entry into the Amended Loan Agreement, the Company borrowed a new term loan in the aggregate principal amount of $ 36.0 million (the "First Amendment Term Loan"), which was substantially used to repay in full the $ 35.0 million Original Term Loan outstanding under the Original Loan Agreement, and we also obtained a secured revolving credit facility in an aggregate principal amount of up to $ 15.0 million (the "Revolving Line").

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The First Amendment also provided for a final payment fee payable to SVB of 2 % of the original principal amount of the First Amendment Term Loan due upon the earlier of the First Amendment Term Loan Maturity Date, termination of the Amended Loan Agreement, acceleration by the Lender following an event of default, or prepayment of the First Amendment Term Loan.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Upon entry into the Third Amended Loan Agreement, we borrowed a new term loan in the aggregate principal amount of $ 36.0 million (the "Third Amendment Term Loan"), which was substantially used to refinance and repay in full the then-outstanding $ 36.0 million First Amendment Term Loan.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Our strong second-quarter performance highlights how our innovation-driven strategy continues to fuel robust engagement across our rapidly expanding physician base, said Laura Francis, Chief Executive Officer.

SEC original ↗SI-BONE, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates, sales force expansion, physician adoption, reimbursement determinations, clinical trial results, government shutdown, and U.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Some of the information contained in this discussion and analysis, or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Our product development strategy focuses on addressing unmet clinical needs while leveraging our existing platform technologies, enabling us to expand physician adoption and increase procedure volumes over time.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Our focus on innovation has resulted in three of our platform technologies being designated as breakthrough devices by the FDA.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These forward-looking statements are based on SI-BONE s current expectations and inherently involve significant risks and uncertainties.

SEC original ↗SI-BONE, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

These risks include SI-BONE s ability to introduce and commercialize new products and indications, SI-BONE s ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.

SEC original ↗SI-BONE, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE s most recent filing on Form 10-K, and SI-BONE s other filings with the Securities and Exchange Commission (SEC) available at the SEC s Internet site (www.

SEC original ↗SI-BONE, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Legal Proceedings 30 Item 1A.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report titled Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations.

SEC original ↗SI-BONE, Inc. — 10-Q Quarterly report10-QAug 4, 2026